- FDA approved Zymeworks’ zanidatamab for HER2-amplified biliary tract cancer on October 1, 2026, covering roughly 12,000–15,000 eligible U.S. patients annually.
- The approval triggers a US$100 million (C$141.8M) milestone from Jazz Pharmaceuticals, significantly strengthening Zymeworks’ balance sheet and commercial runway.
- Peak U.S. BTC sales are modeled at US$400–550 million; a mid-2027 gastric cancer Phase 3 readout could add a further US$2.1 billion peak opportunity.
- ZYME shares jumped ~27% on the NYSE; a Health Canada filing is expected by Q1 2027, opening access for approximately 1,800 Canadian BTC patients per year.
Vancouver-based Zymeworks (TSX: ZYME; NYSE: ZYME) received FDA approval on October 1, 2026 for zanidatamab (brand name: Ziihera) as a second-line treatment for HER2-amplified biliary tract cancer (BTC), including cholangiocarcinoma and gallbladder adenocarcinoma. The approval covers adult patients whose disease progressed on or after gemcitabine-based chemotherapy — a population estimated at roughly 12,000 to 15,000 patients annually in the United States. The decision arrives ahead of the PDUFA date and triggers a US$100 million (C$141.8 million) milestone payment from partner Jazz Pharmaceuticals.
What the Approval Covers — and What It Doesn’t
The FDA greenlit zanidatamab specifically for the second-line BTC setting, using HER2 amplification — not overexpression alone — as the companion diagnostic threshold. This distinction matters commercially: approximately 20–25% of BTC patients harbour HER2 amplification, narrowing the eligible pool but also sharpening the drug’s label and reimbursement case. The approved companion diagnostic is the PATHWAY HER2 (4B5) assay from Roche Diagnostics. Zymeworks and Jazz retain co-commercialization rights in the U.S., with Jazz booking net sales and paying Zymeworks a tiered royalty starting at 15%.
The approval does not extend to gastric or gastroesophageal junction cancers, where zanidatamab is still in Phase 3 trials (HERIZON-GEA-01). That readout, expected in mid-2027, represents the drug’s largest potential indication and could expand the addressable market by an additional US$2.1 billion peak opportunity. A Health Canada New Drug Submission is expected to be filed by Q1 2027, which would make zanidatamab available to Canadian BTC patients — estimated at roughly 1,800 new diagnoses per year — under a priority review pathway.
Commercial Opportunity and Competitive Landscape
Analysts at Leerink Partners and Canaccord Genuity model peak annual U.S. BTC sales of US$400–550 million for zanidatamab, reflecting the drug’s orphan designation, a list price anticipated near US$28,000 per month, and modest competition in the second-line HER2-amplified niche. The main rival is trastuzumab deruxtecan (Enhertu, AstraZeneca/Daiichi Sankyo), which carries a broader HER2-positive label but has not been specifically optimized for BTC and faces its own label limitations in this tumour type. Zanidatamab’s bispecific mechanism — simultaneously binding HER2 domain 2 and domain 4 — differentiates it mechanistically and may support combination strategies currently in early-stage trials.
| Metric | Value |
|---|---|
| U.S. BTC addressable market (HER2-amp) | ~US$1.4B |
| Zanidatamab peak sales estimate (BTC, U.S.) | US$400–550M |
| Jazz milestone triggered | US$100M (C$141.8M) |
| Zymeworks royalty rate (starting) | 15% of net sales |
| GEA-01 gastric readout (next catalyst) | Mid-2027 |
Stock Reaction and Long-Term Thesis
ZYME shares surged 38% in pre-market trading on the NYSE before settling to a gain of approximately 27% by mid-session, putting the stock near C$24.10 on the TSX — still well below the 52-week high of C$31.40 hit in February 2026 when Phase 3 BTC data were first published. The XBI biotech ETF rose 0.55% on the day, suggesting the ZYME move is largely stock-specific rather than sector-driven. For long-term investors, the approval crystallizes a key de-risking event: Zymeworks is now a commercial-stage company with a royalty revenue stream, a funded balance sheet following the Jazz milestone, and multiple shots on goal in HER2-driven oncology. The bear case — that BTC is too small to anchor a standalone biotech — is partially answered by the gastric cancer Phase 3 readout next year, which could reframe the peak sales narrative entirely. Canadian investors should note the USD/CAD rate of 1.4183 provides a meaningful tailwind on U.S.-dollar milestone and royalty receipts flowing to the Vancouver parent.
